CareDx, Inc. (CDNA) Stock Price
CDNAStock
$64.00+326.95%52W
Market Cap$3.31B
P/E18.34x
PEG Ratio—
Div yield—
Beta2.58
CDNA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)253.11%
Price vs S&P 500 (4W)19.12%
VGM Score64.62
P/E Ratio (Annual)18.34x
CDNA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.23 | $0.37 | +59.48%(+$0.14) | |
| Q1 2026 | $0.13 | $0.34 | +161.54%(+$0.21) | |
| Q4 2025 | $0.23 | $0.12 | -47.06%(-$0.11) | |
| Q3 2025 | $0.14 | $0.28 | +97.64%(+$0.14) | |
| Q2 2025 | $0.12 | $0.10 | -18.03%(-$0.02) |
CDNA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.00
4.00
4.00
4.08
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CELCCelcuity Inc. Common Stock | — | — | D | — | — | — | -244.6% | $56.58 |
About CareDx, Inc.
CareDx is a precision medicine company providing genomics-based testing solutions for transplant patients. Its primary products include AlloSure and AlloMap, diagnostic tests that monitor transplant function and rejection risk. The company generates most revenue from testing services in the United States, serving transplant recipients and caregivers throughout the patient journey.